3:36 PM
 | 
Nov 21, 2012
 |  BC Extra  |  Top Story

Aetna adds coverage for Qsymia, Belviq

Health benefits manager Aetna Inc. (NYSE:AET) will now reimburse obesity drugs Belviq lorcaserin from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) and Qsymia phentermine/topiramate from Vivus Inc. (NASDAQ:VVUS). Aetna said in a policy bulletin that it considers Qsymia and Belviq along with clinical supervision "medically necessary" for members who failed to lose at least one pound per week...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >